- Home
- ECBK vs VERU Comparison
ECBK vs VERU Comparison
Compare ECBK & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECBK
- VERU
- Stock Information
- Founded
- ECBK 1919
- VERU 1971
- Country
- ECBK United States
- VERU United States
- Employees
- ECBK N/A
- VERU N/A
- Industry
- ECBK Banks
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- ECBK Finance
- VERU Health Care
- Exchange
- ECBK Nasdaq
- VERU Nasdaq
- Market Cap
- ECBK 134.8M
- VERU 107.2M
- IPO Year
- ECBK N/A
- VERU 1990
- Fundamental
- Price
- ECBK $15.05
- VERU $0.65
- Analyst Decision
- ECBK
- VERU Strong Buy
- Analyst Count
- ECBK 0
- VERU 4
- Target Price
- ECBK N/A
- VERU $4.00
- AVG Volume (30 Days)
- ECBK 6.6K
- VERU 1.1M
- Earning Date
- ECBK 10-24-2024
- VERU 02-06-2025
- Dividend Yield
- ECBK N/A
- VERU N/A
- EPS Growth
- ECBK N/A
- VERU N/A
- EPS
- ECBK 0.39
- VERU N/A
- Revenue
- ECBK $24,711,000.00
- VERU $16,886,419.00
- Revenue This Year
- ECBK N/A
- VERU N/A
- Revenue Next Year
- ECBK N/A
- VERU N/A
- P/E Ratio
- ECBK $38.21
- VERU N/A
- Revenue Growth
- ECBK N/A
- VERU N/A
- 52 Week Low
- ECBK $11.39
- VERU $0.36
- 52 Week High
- ECBK $15.75
- VERU $1.92
- Technical
- Relative Strength Index (RSI)
- ECBK 49.93
- VERU 42.01
- Support Level
- ECBK $14.67
- VERU $0.60
- Resistance Level
- ECBK $15.37
- VERU $0.82
- Average True Range (ATR)
- ECBK 0.29
- VERU 0.07
- MACD
- ECBK -0.04
- VERU -0.01
- Stochastic Oscillator
- ECBK 35.19
- VERU 22.32
About ECBK ECB Bancorp Inc.
ECB Bancorp Inc operates as a bank holding company of Everett Co-operative Bank. The firm through its subsidiary engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, and multifamily real estate loans, construction and land loans and home equity lines of credit.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.